Following the world’s first successful xenotransplant of a genetically engineered pig kidney into a living human patient, eGenesis—a biotech company committed to transforming the treatment of organ failure—is closer than ever to accomplishing its ultimate mission: solving the global organ transplant crisis.

To get a sense of what it took to achieve this historic breakthrough, IQ spoke with eGenesis CEO, Dr. Mike Curtis, and Chief People Officer, Elizabeth Roberts, about the incredible milestone and what's next on the company's horizon.

Artificial intelligence has the potential to transform numerous industries, yet experts believe it could also elevate the best of what it means to be human. This leaves many pundits wondering: will we seize the opportunity?

Joining the discussion are special guests John Kalil and Steve Steinberg, partners at Elixirr, a global consulting firm specializing in AI, data, innovation, and end-to-end digital solutions—and parent company of Insigniam.

With 25 years of strategy, technology, operations, and business transformation experience, Mr. Kalil often advises Elixirr clients just beginning their AI-journey.

In addition to being a fellow Elixirr partner, Mr. Steinberg is also CEO of Responsum, an artificial intelligence company that uses generative AI, large language models (LLMs), and other cutting-edge technology to drive business performance.

As part of Elixirr, both Mr. Kalil and Mr. Steienberg support clients seeking strategic AI guidance and bespoke generative AI solutions to drive massive growth and transformation.

In our second installment on how Environmental, Social, and Governance (ESG) programs can create a competitive advantage for enterprises worldwide, Insigniam consultant Tracy Holloman welcomes Dr. Chuck Wallington, Executive Vice President and Chief Marketing & Communications Officer at Cone Health—a not-for-profit network of healthcare providers serving people in North Carolina—who shares his personal experience and perspective on the social aspect of ESG, and what other executives should know when investing in their own ESG programs.